SALT LAKE CITY, Aug. 10 /CNW/ -- ("WorldHeart", Nasdaq: WHRT) World Heart
Corporation, a pioneer in cardiac assist technologies, announced today that it
has appointed Morgan Brown as Executive Vice President and Chief Financial
Officer. Mr. Brown brings over 16 years of experience to WorldHeart.
Mr. Brown joins WorldHeart from Lifetree Clinical Research where he was
Chief Financial Officer and Senior Vice President since 2008. While at
Lifetree Clinical Research, Mr. Brown oversaw the accounting, finance, human
resource, facility and information technology departments.
Previously, Mr. Brown was with NPS Pharmaceuticals Inc., a Russell 2000
public company, from 2000 to 2008, where he served as Vice President Finance
and Treasurer. During his tenure at NPS Mr. Brown was involved in numerous
financings as well as merger and acquisition activities.
Before NPS, Mr. Brown, 40, worked for KPMG LLP in Salt Lake City. Mr.
Brown managed multiple audit engagements, servicing private and publicly owned
clients. Mr. Brown is a licensed certified public accountant in Utah and
earned a master's degree in business administration from the University of
Utah and a bachelor's degree in accounting from Utah State University.
Alex Martin, WorldHeart's President and CEO commented, "I join
WorldHeart's Board of Directors and employees in welcoming Morgan to
WorldHeart. Morgan brings a wealth of experience in finance and accounting
that will be invaluable as WorldHeart transitions its corporate headquarters
to Salt Lake City, advances its clinical development programs and grows its
In addition to his other duties, Mr. Brown will manage the move of the
World Heart Headquarters from Oakland, California to Salt Lake City, Utah.
About World Heart Corporation
WorldHeart is a developer of mechanical circulatory support systems
headquartered in Salt Lake City, Utah with additional facilities in Oakland,
California, USA and Herkenbosch, The Netherlands. WorldHeart's registered
office is in Ottawa, Ontario, Canada.
Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995
and include all statements relating to the advancement of WorldHeart's
clinical development programs and the growth of its overall business, as well
as other statements that can be identified by the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will," "should,"
"seeks," "plans," "anticipates," or "intends" or the negative of those terms,
or by discussions of strategy or intentions. Investors are cautioned that all
forward-looking statements involve risk and uncertainties, including without
limitation: WorldHeart's need for additional capital in the future; risks in
product development and market acceptance of and demand for WorldHeart's
products; and other risks detailed in WorldHeart's filings with the U.S.
Securities and Exchange Commission, including without limitation its Annual
Report on Form 10-K for the year ended December 31, 2008 and its Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009.
For further information:
For further information: Mr. J Alex Martin, +1-801-303 4352, or Ms.
Peggy Allman, +1-510-563-4721, both of World Heart Corporation Web Site: